Open AccessPD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond
Author(s) -
Tingrui Han,
Yupeng Li,
Xintong Wang
Publication year - 2022
Publication title -
highlights in science, engineering and technology
Language(s) - English
Resource type - Journals
ISSN - 2791-0210
DOI - 10.54097/hset.v8i.1114
Subject(s) - avelumab , durvalumab , atezolizumab , nivolumab , pembrolizumab , medicine , blockade , tremelimumab , immunotherapy , oncology , ipilimumab , clinical trial , cancer , receptor